Jeff Vacirca, CEO of New York Cancer & Blood Specialists and co-founder of OneOncology, and Pentagon health official Stephen Ferrara have joined the Trump administration’s shortlist to lead the FDA, according to a Bloomberg report Friday. For oncology clinicians and drug developers, the addition of an oncology practice leader to the candidate pool could shape how the agency approaches cancer care delivery, diagnostics and review priorities.

Why It Matters To Oncology

• Vacirca’s background in community oncology could give clinicians and drug developers a clearer line of sight into how a future FDA commissioner might weigh real-world treatment access, practice economics and cancer drug uptake.

• His ties to OneOncology may be especially relevant for stakeholders tracking policy around oncology pathways, site-of-care shifts and the integration of new therapeutics into large community networks.

• Ferrara, a radiologist with federal health leadership experience, would bring a different lens — potentially elevating imaging, operational oversight and cross-agency coordination.

The Financials

• The commissioner shortlist update lands alongside several market-moving biotech developments: Biogen is binning or pausing most inherited Apellis research programmes after its $5.6 billion acquisition.

• Biogen is instead prioritising commercial execution for Syfovre and Empaveli, which generated $689 million last year and are projected to grow at a mid- to high-teens rate through at least 2028.

• Elsewhere, Lycia Therapeutics raised an oversubscribed $75 million series D to advance lysosomal protein degrader programmes, with participation from Lilly among other investors.

What They're Saying

• Bloomberg reported that Vacirca and Ferrara are now on the shortlist, joining White House aide Heidi Overton as potential nominees.

• CNN previously reported that former FDA commissioner Ned Sharpless and Richard Pops were also being vetted.

• Vacirca is described as a supporter of HHS Secretary Robert F. Kennedy Jr., a detail that may matter as the administration weighs alignment on broader health policy.

What's Next

• The White House has not announced a final nominee, so oncology stakeholders should watch for signals on regulatory philosophy, especially around accelerated approvals, diagnostics and manufacturing oversight.

• Recent FDA complete response letters to Lantheus and Sobi — both tied to manufacturing issues rather than safety or efficacy — underscore that CMC execution remains a key pressure point for developers.

• If Vacirca advances, clinicians and oncology companies will likely scrutinise how his community-practice experience could translate into FDA decision-making on cancer drugs and related technologies.